A Study of MORAb-202 in Participants With Solid Tumors

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

The primary objective of this study is to evaluate the tolerability and safety profile of MORAb-202 in participants with solid tumors.

Phase 1

Eisai Inc.